Our ambition is to change lives by changing the course of blood cancer.
We’re committed to bringing the potential power of telomerase inhibition to patients with imetelstat.
Latest Updates
Research & Development
Geron announces FDA acceptance of New Drug Application for imetelstat for the treatment of transfusion dependent anemia in patients with lower risk myelodysplastic syndromes (LR MDS)
Learn moreEvents
Investor Event

Geron to present at three investor conferences in November
John Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at three investor conferences this month.
Investor Event

Watch the replay of our third quarter financial results webcast
Geron management shared third quarter financial results and business highlights.
Research & Development
What if you could kill cancer cells by targeting the enzyme that drives their uncontrolled growth?
Geron is tirelessly pursuing blood cancer treatments with the potential to extend and enhance lives through the unique mechanism of action of telomerase inhibition. Our first-in-class telomerase inhibitor, imetelstat, harnesses Nobel Prize-winning science in a treatment that may alter the underlying drivers of disease.
Learn about imetelstatPublications
Research & Development
Continuous Transfusion Independence with Imetelstat in Lower Risk MDS in IMerge Phase 3
Platzbecker, et. al.
Research & Development
Analysis of Patient Reported Fatigue in IMerge Phase 3 Trial of Imetelstat vs. Placebo in Lower Risk MDS
Sekeres, et. al.
Bringing first-in-class imetelstat to patients
Learn how we’re building on Nobel Prize-winning science
We are on a mission to extend and enhance lives
Discover more about our commitment to patients